针对转移性结直肠癌的免疫检查点抑制剂:系统性审查
Alice Gilson1, Vincent Tan2, Thibaud Koessler3
1Division of Digestive Surgery, Geneva University Hospitals, 1205 Geneva, Switzerland.
Cancers
|July 12, 2025
概括
检查点抑制剂对转移性结直肠癌与微卫星不稳定性 (MSI mCRC) 有效. 然而,免疫疗法在微卫星稳定 (MSS CRC) 中表现出有限的成功,组合疗法提供了混合的结果和潜在的副作用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 结肠直肠癌 (CRC) 是一个重大的全球健康挑战.
- 免疫疗法,特别是检查点抑制剂,已成为高级CRC的关键治疗策略.
- 了解这些药物在不同CRC亚型中的疗效至关重要.
研究的目的:
- 系统地审查对转移性结直肠癌 (mCRC) 中检查点抑制剂的临床证据.
- 评估免疫治疗在MSI和MSSmCRC亚型中的疗效和安全性.
- 评估组合策略在mCRC治疗中的作用.
主要方法:
- 2019年1月至2025年1月期间发表的临床试验和随机对照试验 (RCT) 的系统审查.
- 在Medline,Web of Science和Cochrane数据库中进行了搜索.
- 主要结局包括无进展生存 (PFS),总生存 (OS) 和客观反应率 (ORR).
主要成果:
- 检查点抑制剂在微卫星不稳定性 (MSI) 转移性结直肠癌 (mCRC) 中表现出显著的疗效.
- 免疫疗法在微卫星稳定性 (MSS) mCRC中效果较差,组合策略产生混合的结果.
- 与治疗相关的3级以上的不良事件 (TRAEs) 经常在组合治疗方案中观察到.
结论:
- 免疫疗法已经改变了MSI mCRC的治疗环境.
- 目前针对MSS CRC的免疫治疗方法仍然没有令人信服.
- 组合策略和新型药物显示出希望,但需要进一步研究疗效和安全性.
相关概念视频
01:27Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K